SEC Company Response from Coherus Oncology, Inc. (CHRS) (CIK 0001512762) (CHRS) — Nov 3, 2014
Coherus Oncology, Inc. (CHRS) (CIK 0001512762)
Date: Nov. 3, 2014 · CIK: 0001512762 · Accession: 0001193125-14-393914
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-198936
Letter
Prepared by R.R. Donnelley Financial -- Company Acceleration Request
November 3, 2014
VIA EDGAR AND E-MAIL
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-6010
Attention: Jeffrey P. Riedler, Assistant Director
Tabatha McCullom
James Rosenburg
Daniel Greenspan
Scot Foley
Re: Coherus BioSciences, Inc.
Registration Statement on Form S-1 (Registration No. 333-198936)
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-198936) (the “Registration Statement”) of Coherus BioSciences, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:30 p.m., Washington, D.C. time, on November 5, 2014, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Benjamin Potter at (650) 470-4809.
The Company acknowledges the following:
•
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
201 Redwood Shores Parkway, Suite 200, Redwood City, CA 94065 Main: 650.649.3530
Page 1
Thank you for your assistance in this matter.
Very truly yours,
COHERUS BIOSCIENCES, INC.
Show Raw Text
CORRESP 1 filename1.htm Prepared by R.R. Donnelley Financial -- Company Acceleration Request November 3, 2014 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Jeffrey P. Riedler, Assistant Director Tabatha McCullom James Rosenburg Daniel Greenspan Scot Foley Re: Coherus BioSciences, Inc. Registration Statement on Form S-1 (Registration No. 333-198936) Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-198936) (the “Registration Statement”) of Coherus BioSciences, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:30 p.m., Washington, D.C. time, on November 5, 2014, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Benjamin Potter at (650) 470-4809. The Company acknowledges the following: • should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. 201 Redwood Shores Parkway, Suite 200, Redwood City, CA 94065 Main: 650.649.3530 Page 1 Thank you for your assistance in this matter. Very truly yours, COHERUS BIOSCIENCES, INC. By: /s/ Dennis M. Lanfear Dennis M. Lanfear President and Chief Executive Officer cc: Alan C. Mendelson, Esq., Latham & Watkins LLP Benjamin A. Potter, Esq., Latham & Watkins LLP Alan F. Denenberg, Esq., Davis Polk & Wardwell LLP Stephen Salmon, Esq., Davis Polk & Wardwell LLP 201 Redwood Shores Parkway, Suite 200, Redwood City, CA 94065 Main: 650.649.3530 Page 2